Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News enGene Holdings Inc ENGN

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
enGene Holdings Inc. is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ENGN)

enGene Reports First Quarter 2025 Financial Results and Provides Business Update

Business Wire 12 days ago

enGene to Participate in the Leerink Partners Global Healthcare Conference

Business Wire March 4, 2025

enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Business Wire February 4, 2025

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire January 31, 2025

enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)

Business Wire January 30, 2025

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire December 30, 2024

enGene Reports Full Year 2024 Financial Results and Provides a Business Update

Business Wire December 19, 2024

enGene to Participate in Upcoming Investor Conferences

Business Wire November 25, 2024

enGene to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Business Wire November 5, 2024
View More News ››

Opinion & Analysis (NDAQ:ENGN)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ENGN)

ENGN

We are heading to $10..slowly but surely....exactly the  range it should be along the  study timing  yeahhh
masterthink - January 2, 2025

RE:yeahhhhhh!!

PATIENT INVESTORS WIL BE REWARDED BIG TIME HERE.... THE ODDS ARE OBVIOUSLY VERY GOOD ....THANKS GOD TO HELP THOSE CANCEROUS ...
masterthink - December 31, 2024

yeahhhhhh!!

Boston & Montreal = a very good mix into  bladder cancer research....
masterthink - December 30, 2024
View more Bullboard ››

Lahontan Gold Corp.

Lahontan Gold Corp.

Lahontan Gold Corp. is a Canada-based mineral exploration company. The Company is engaged in the identification, acquisition, ...
View More »